Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal neurological diseases that include Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, camel spongiform encephalopathy (CSE) in camels (Babelhadj et al
requirement to perform a risk assessment and to address specific questions of the zoonotic potential of these prion agents. Advice has been sought on some occasions by the European Commission in order to provide updated information on the zoonotic potential of TSEs other than BSE.
In the past, EFSA and the former Scientific Steering Committee (SSC) of the European Commission were asked to reflect on the zoonotic potential of CWD and the possible role of cervids in the transmission of TSEs to humans. In 2003, the SSC concluded that a theoretical risk of prion transmission to humans consuming products of CWD-affected cervids of all ages in countries where CWD exists cannot be excluded. The SSC also concluded that the early and widespread involvement of tissues in CWD infected animals did not allow specified risk materials (SRM) to be defined. Neither was it possible to define a lower age cut-off for cattle in relation to BSE. In 2004, the EFSA concluded that even although human TSE-exposure risk through consumption of game from European cervids could be assumed to be either non-existent or minor, no final conclusion could be drawn due to the overall lack of scientific data (EFSA, 2004) .
In Based on these developments, a number of questions were raised by the European Commission. Specifically, should the current assumption on the number of people who may develop vCJD in the future be reviewed? How does this impact on the current assumptions regarding transmissibility through blood transfusion and tissue/cells transplantation? Does this affect the number of individuals at risk of developing vCJD following a transfusion/ transplantation? Are there measures that can be implemented to reduce the potential risk?
Protein misfolding neurodegenerative diseases Some research suggests that other proteins demonstrating prion-like behaviour play a role in other neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, as well as amyotrophic lateral sclerosis (ALS) (Guo et al., 2014) . Recent work in humans suggest that Aβ can aggregate into structural variants with distinct pathological traits. By using extracted fibrils from the brains of patients with Alzheimer's disease (AD) to seed the aggregation of synthetic Aβ, it has been shown that Aβ assumes a single, dominant conformation of a given brain with structural heterogeneity among AD patients.
A prion-like mechanism has been proposed to explain the apparent proliferation of α-synuclein aggregates in the brains of Parkinson's disease patients. Whether prion-like Introduction to Current Research on Prions conformational templating occurs when α-synuclein aggregate strains are propagated in vivo or in vitro remains unclear.
Mutant forms of the Cu-Zn superoxide dismutase 1 (SOD1) gene are known to be associated with 10% of familial ALS cases. Some of these mutations are associated with a disease that progresses rapidly, resulting in death within 3 years, whereas others are associated with a relatively slow disease course, with the patient surviving for more than 20 years. One potential explanation for this variability in disease progression is that the SOD1 mutation exhibits prion strain-like properties that may affect their ability to propagate within the central nervous system. Pecho-Vrieseling et al. (2014) suggest the protein that creates the aggregates found in Huntington's disease patients, mutant huntingtin (mHTT), may spread from cell to cell. These studies provide a valuable insight into what is currently understood about the role of protein aggregates and Huntington's disease.
Prion clearance
Progressive accumulation of PrP Sc can occur only if conversion of PrP C to PrP Sc is faster than PrP Sc clearance. Therefore, studying the clearance of prions is arguably as important as studying their generation. Prnp -/-mice develop more or less normally yet cannot replicate prions, making them a perfect model to study the half-life of the prion. On inoculation, residual infectivity all but disappears within 4 days, indicating that prions, which are commonly regarded as the most robust pathogens yet described, can be cleared in vivo with astonishing efficiency and speed. The identification of molecules and cells involved in prion clearance will be of great importance in the development of therapeutics of prion diseases (Aguzzi et al., 2012) .
Neprilysin is a metalloprotease that is known to degrade extracellular amyloid protein such as Aβ. However, mice lacking or overexpressing neprilysin show no changes in prion pathogenesis. Therefore, prion clearance may be affected by extracellular proteases other than neprilysin, or by different mechanisms altogether (Glatzel et al., 2005) . In organotypic cerebellar slices, the pharmacogenetic ablation of microglia led to a 15-fold increase in prion titres (Falsig et al., 2008) , suggesting that microglia are the primary effectors of prion clearance. But how do microglia identify prions as targets for destruction? Milk fat globule epidermal growth factor 8 (Mfge8), a bridging molecule mediating phagocytosis of apoptotic cells, may represent a crucial link. Mfge8 -/-mice showed accelerated prion pathogenesis, accompanied by reduced clearance of cerebral apoptotic bodies and increased PrP Sc accumulation and prion titre (Kranich et al., 2010) , suggesting Mfge8-mediated prion clearance in prion-infected mouse brain. Interestingly, these changes were observed in the C57BL/6x129Sv but not in the C57BL/6 genetic background. Therefore, besides Mfge8, other molecules involved in the phagocytosis of apoptotic cells could have the potential to clear prions in vivo. These newly identified molecules involved in the pathogenesis in prion diseases need to be studied in more detail.
